New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 26, 2013
09:02 EDTARWRArrowHead Research to publish data of ARC-520 study
Arrowhead Research announced the publication of data demonstrating multi-log reductions in hepatitis B viral DNA and proteins lasting over 30 days after a single injection in animal models. This suggests that Arrowhead's RNAi-based candidate ARC-520 has the potential to treat chronic hepatitis B virus infection in a fundamentally different manner, with the goal of achieving a functional cure. The paper, entitled "Hepatocyte-targeted RNAi therapeutics for the treatment of chronic hepatitis B virus infection," by Wooddell et al, was published online ahead of print in the journal Molecular Therapy. In the publication, Arrowhead scientists describe the use of a novel Dynamic PolyConjugate technology to deliver small interfering RNAs designed against the hepatitis B virus.
News For ARWR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 18, 2015
10:37 EDTARWROptions with decreasing implied volatility
Options with decreasing implied volatility: NLNK ARWR CTRP ZIOP CLNE ARIA VHC AOL KING XON PEIX
May 15, 2015
10:20 EDTARWROptions with decreasing implied volatility
Options with decreasing implied volatility: NLNK ARWR CTRP RAX KING AOL WPZ RL Z MBI
May 14, 2015
10:56 EDTARWROptions with decreasing implied volatility
Subscribe for More Information
May 13, 2015
11:08 EDTARWROptions with decreasing implied volatility
Subscribe for More Information
May 12, 2015
10:16 EDTARWROptions with decreasing implied volatility
Options with decreasing implied volatility: NDLS WTW FUEL AOL LC NLNK ZU CYBR ARWR HZNP
May 11, 2015
16:09 EDTARWRArrowhead reports Q2 EPS (51c), consensus (34c)
Reports Q2 revenue $43,750, consensus $110,000.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use